Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drug-Drug Interaction Study of Clifutinib
NCT07341672Phase 1Not yet recruiting
- Sponsor
- Sunshine Lake Pharma
- Start
- Dec 2026
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of clifutinib (4 arms), sponsored by Sunshine Lake Pharma. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration and 4 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
clifutinib
Beyond the preview
Go deeper on NCT07341672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07341672.